3SBio Calls Extraordinary Meeting to Approve Mandi Spin-Off Dividend

The latest announcement is out from 3SBio ( (HK:1530) ).

3SBio Inc. has called an extraordinary general meeting for 23 April 2026 in Shenyang to seek shareholder approval for a conditional special dividend in the form of a distribution in specie of all the shares it holds in subsidiary Mandi Inc. to qualifying shareholders. The board is also asking shareholders to authorize directors with broad discretion to determine the final terms and mechanics of the spin-off-related distribution, a step that would facilitate execution of the transaction and potentially reshape the group’s portfolio and capital allocation for investors.

The meeting notice details standard proxy and voting arrangements, including the ability for shareholders to appoint proxies and requirements for submitting proxy forms ahead of the meeting, ensuring that both local and overseas investors can participate in the decision. Joint holders’ voting order, treatment of any treasury shares, and procedural rules around attendance and proxy revocation are also clarified, underscoring the company’s emphasis on formal governance as it pursues the proposed spin-off and associated dividend.

The most recent analyst rating on (HK:1530) stock is a Hold with a HK$25.00 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.

More about 3SBio

3SBio Inc., incorporated in the Cayman Islands and headquartered in Shenyang with a principal office in Hong Kong, is a Hong Kong-listed company focused on the healthcare and biopharmaceutical sector. The group operates through multiple entities and uses general meetings to seek shareholder approval for major corporate actions affecting its capital structure and investments.

Average Trading Volume: 24,254,818

Technical Sentiment Signal: Buy

Current Market Cap: HK$57.46B

Find detailed analytics on 1530 stock on TipRanks’ Stock Analysis page.